More recently, a class of reversible inhibitors known as selective inhibitors of nuclear export (SINEs) was developed [107], and among them, KPT-330 (selinexor) [108] and KPT-8602 (eltanexor) (Figure 4) [109] showed anti-leukemic activity by inhibiting the interaction between NPM1-mut and XPO1, improving the tolerability and also synergistic activity with BCL-2 inhibitors by increasing apoptosis in NPM1-AML cells [110], as currently being evaluated in early phase trials (NCT03955783). This evidence concerns the gene NPM1 and acute myeloid leukemia.